The Opposing Roles of IL-10 and IFN-gamma in Macrophage Activation Syndrome

描述（由申请人提供）：巨噬细胞活化综合征（MAS）是许多儿科风湿病的危及生命的并发症。MAS包括高水平的炎性细胞因子、多系统器官衰竭、凝血障碍和噬血细胞作用的发展。它与另一种遗传性细胞因子风暴综合征家族性噬血细胞性巨噬组织细胞增多症（fHLH）的外观相似。然而，与fHLH不同，MAS患者没有与疾病相关的基因突变。因此，导致疾病的初始事件在MAS中可能不同于fHLH。我们最近开发了一种新的MAS小鼠模型，这是第一个在不需要遗传操作或感染的情况下产生MAS样疾病的模型。该模型提供了MAS患者倾向于升高炎症Toll样受体（TLR）激活状态的观察结果之间的第一个联系。通过使用重复的TLR 9刺激，小鼠产生MAS样综合征。与fHLH一样，该疾病由干扰素-γ（IFN？）介导。与fHLH不同，这种IFN？大部分是在骨髓细胞中产生的，再次证明了MAS和fHLH之间的差异以及对独特模型的需求。该模型还证明了白细胞介素-10（IL-10）在防止MAS和噬血细胞作用的发展中的关键作用。该提案旨在确定IFN？的细胞应答者，这些反应的性质，以及使用互补遗传和药理学技术在MAS中保护性IL-10的来源。骨髓嵌合体将用于产生缺乏IFN受体的小鼠？对特定的细胞群进行检测以确定响应细胞。将使用连续转移技术来确定对产生保护性IL-10应答重要的细胞类型。将给予重组细胞因子以研究细胞因子暴露与TLR刺激之间的时间关系。从这些研究中产生的数据将提供一个合理的目标IFN？和IL-10，以及它们在治疗MAS中的相关细胞应答。这将标志着在开发MAS特异性疗法方面向前迈出了重要的一步，而不是不适当地从fHLH方案中借用护理标准。

DESCRIPTION (provided by applicant): Macrophage Activation Syndrome (MAS) is a life threatening complication of many pediatric rheumatology diseases. MAS consist of high levels of inflammatory cytokines, multi-system organ failure, coagulopathy, and the development of hemophagocytosis. It bears a similar appearance to another genetic cytokine storm syndrome, Familial Hemophagocytic Lymphohistiocytosis (fHLH). However, unlike fHLH, patients with MAS do not have genetic mutations associated with the disease. According, the initial events leading to the disease are likely different in MAS than in fHLH. We have recently developed a novel mouse model of MAS, the first model to produce an MAS-like disease without the need for genetic manipulations or infections. This model provides the first link between the observations that patients with MAS tend to heightened states of inflammatory Toll-like receptor (TLR) activation. By using repeated TLR9 stimulation, mice develop an MAS-like syndrome. Like fHLH, the disease is mediated by Interferon-gamma (IFN?). Unlike fHLH, this IFN? is made in large part myeloid cells, again demonstrating the difference between MAS and fHLH and the need for unique models. This model has also demonstrated a critical role for Interleukin-10 (IL-10) in protecting against the development of MAS and hemophagocytosis. This proposal seeks to identify the cellular responders to IFN?, the nature of these responses, and the source of protective IL-10 in MAS using complementary genetic and pharmacologic techniques. Bone marrow chimera will be used to generate mice lacking the receptors for IFN? on specific cellular populations to determine the responding cells. Adoptive transfer techniques will be used to determine the cell type important for making the protective IL-10 response. Recombinant cytokines will be administered to investigate the temporal relationship between cytokine exposure and TLR stimulus. The data generated from these studies will provide a basis for rational targeting of IFN? and IL-10, and their associated cellular responses in treating MAS. This will mark an important step forward in developing MAS specific therapies as opposed to the standard of care of borrowing inappropriately from the fHLH protocols.